| 21 Oct 2012 | New versus old oral antiplatelet agents: which drug and how long? | U Zeymer (Ludwigshafen, Germany) | public |
| 21 Oct 2012 | Practical considerations - Dose and timing of ASA and P2Y12 inhibitors: is genetic or in vitro testing clinically useful? | R F Storey (Sheffield, United Kingdom) | public |
| 21 Oct 2012 | Is there still a role for IV antiplatelet agents (GP IIb/IIIa inhibitors, cangrelor)? | F Schiele (Besancon, France) | public |
| 21 Oct 2012 | Specific situations: patients. | M Lettino (Milano, Italy) | public |
| 22 Oct 2012 | Patients with general comorbidities. | A Budaj (Warsaw, Poland) | public |
| 22 Oct 2012 | Patients with acute heart failure. | ICC van der Horst (Groningen, Netherlands) | public |
| 22 Oct 2012 | Patients with renal failure. | F Schiele (Besancon, France) | public |
| 22 Oct 2012 | Patients with geriatric syndromes. | H Bueno (Madrid, Spain) | public |
| 22 Oct 2012 | The fate of patients triaged in the field. | P M Clemmensen (Copenhagen, Denmark) | public |
| 22 Oct 2012 | Network models for reperfusion in STEMI patients and emergency organisation. | K Huber (Vienna, Austria) | public |
| 22 Oct 2012 | Pre-hospital anti thrombotic treatment before mechanical reperfusion: new perspectives. | L De Luca (Roma, Italy) | public |
| 21 Oct 2012 | The challenge of recognising cardiogenic shock. | C Hassager (Copenhagen, Denmark) | public |
| 21 Oct 2012 | To fill or not to fill - Balancing input and output. | V-P Harjola (Helsinki, Finland) | public |
| 21 Oct 2012 | Inotropes - Still a role? | J T Parissis (Athens, Greece) | public |
| 21 Oct 2012 | Managing futility. | S Price (London, United Kingdom) | public |
| 22 Oct 2012 | Is intubation the "gold standard" in out of hospital resuscitation? | B W Boettiger (Koln, Germany) | public |
| 22 Oct 2012 | Cooling during and after cardiac arrest - Where is the evidence taking us? | J Bro-Jeppesen (Copenhagen, Denmark) | public |
| 22 Oct 2012 | The post cardiac arrest syndrome - Emerging concepts. | N I Nikolaou (Athens, Greece) | public |
| 21 Oct 2012 | Pathophysiology and outcome of incessant VT, electrical storm and acute cardiac failure. | F Braunschweig (Stockholm, Sweden) | public |
| 21 Oct 2012 | Pharmacological treatment options | K Adalet (Istanbul, Turkey) | public |
| 21 Oct 2012 | Catheter ablation of incessant VT and electrical storm. | J Kautzner (Prague, Czech Republic) | public |
| 21 Oct 2012 | Novel approaches to treat acute cardiac failure. | E Gronda (Sesto S. Giovanni, Italy) | public |
| 22 Oct 2012 | Predictors and outcomes of bleedings. | D C L Gulba (Oberhausen, Germany) | public |
| 22 Oct 2012 | Therapeutic measures in patients with bleedings. | A Budaj (Warsaw, Poland) | public |
| 21 Oct 2012 | The principles and pitfalls of mechanical circulatory support. | P Vranckx (Hasselt, Belgium) | public |
| 21 Oct 2012 | Surgical mechanical circulatory support. | P M Petrou (Nicosia, Cyprus) | public |
| 21 Oct 2012 | Transcatheter circulatory support. | C J M Vrints (Edegem, Belgium) | public |
| 21 Oct 2012 | When to refer for mechanical circulatory support, the INTERMACS registry. | S Price (London, United Kingdom) | public |
| 20 Oct 2012 | The choice of antithrombotic therapy. | K Huber (Vienna, Austria) | public |
| 20 Oct 2012 | The choice of antiplatelet therapy. | R F Storey (Sheffield, United Kingdom) | public |
| 20 Oct 2012 | Who needs intervention? | M M Degertekin (Istanbul, Turkey) | public |
| 20 Oct 2012 | Beta blockers and ACE inhibitors - For all? | D Zahger (Beer Sheva, Israel) | public |
| 20 Oct 2012 | Atrial fibrillation and death after STEMI: risk marker or casual mediator? | M M Gulizia (Catania, Italy) | public |
| 20 Oct 2012 | Rate control versus rhythm control in NSTEMI. | G Kudaiberdieva (Adana, Turkey) | public |
| 20 Oct 2012 | Atrial fibrillation in acute heart failure. | A S Manolis (Glyfada-Athens, Greece) | public |